Alnylam Pharmaceuticals (ALNY) EPS (Basic) (2016 - 2025)
Historic EPS (Basic) for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $0.84.
- Alnylam Pharmaceuticals' EPS (Basic) rose 22923.08% to $0.84 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1, marking a year-over-year increase of 19677.42%. This contributed to the annual value of $2.39 for FY2025, which is 20963.3% up from last year.
- According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' EPS (Basic) is $0.84, which was up 22923.08% from $1.91 recorded in Q3 2025.
- Alnylam Pharmaceuticals' EPS (Basic)'s 5-year high stood at $1.91 during Q3 2025, with a 5-year trough of -$3.32 in Q3 2022.
- For the 5-year period, Alnylam Pharmaceuticals' EPS (Basic) averaged around -$1.01, with its median value being -$1.24 (2023).
- The largest annual percentage gain for Alnylam Pharmaceuticals' EPS (Basic) in the last 5 years was 31954.02% (2025), contrasted with its biggest fall of 29230.77% (2025).
- Alnylam Pharmaceuticals' EPS (Basic) (Quarter) stood at -$2.18 in 2021, then increased by 21.86% to -$1.71 in 2022, then soared by 36.07% to -$1.09 in 2023, then surged by 40.37% to -$0.65 in 2024, then skyrocketed by 229.23% to $0.84 in 2025.
- Its last three reported values are $0.84 in Q4 2025, $1.91 for Q3 2025, and -$0.51 during Q2 2025.